Ferring to co-promote Xanodyne’s Zipsor pain drug

Ferring Pharmaceuticals has agreed to co-promote the diclofenac-based pain treatment Zipsor with Xanodyne.

This agreement will see Ferring receive royalty payments on the sales it generates, with its marketing activities set to be aimed at orthopaedic surgeons, rheumatologists, sports medicine physicians and physiatrists.

The non-steroidal anti-inflammatory drug has been approved by regulators since 2009.

William Garbarini, vice-president of the orthopaedics and urology business unit for Ferring Pharmaceuticals, said the treatment represents “an exciting addition to our current orthopaedic product portfolio”.

He added that the company “welcomes the opportunity to expand our offering to the orthopaedic community by helping orthopaedic surgeons and rheumatologists treat patients with acute pain”.

The firm also operates in therapeutic areas such as endocrinology, osteoarthritis and urology, developing treatments such as Pentasa and Minirin.